Search - tctmd.com

Displaying 21 - 40 of 133

Sort: Relevancy | Date

Bleeds on Anticoagulants for A-Fib Can Unveil Occult Cancers

News Daily News

Bleeds on Anticoagulants for A-Fib Can Unveil Occult Cancers

November 06, 2020

H. Pylori in ACS: Could Tests and Treatment Beat Back the Bleeds?

News Daily News

H. Pylori in ACS: Could Tests and Treatment Beat Back the Bleeds?

November 05, 2020

News Daily News

Fewer MIs With Prasugrel Than Ticagrelor in STEMI Patients: ISAR-REACT 5

Michael O'Riordan

November 03, 2020

TCTMD’s Top 10 Most Popular Stories for October 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2020

October 30, 2020

Superiority of Ticagrelor Over Clopidogrel in ACS Questioned

News Daily News

Superiority of Ticagrelor Over Clopidogrel in ACS Questioned

October 29, 2020

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

News Daily News

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

Michael O'Riordan

October 28, 2020

More Circulating Omega-3s May Boost Prognosis After STEMI

News Daily News

More Circulating Omega-3s May Boost Prognosis After STEMI

October 26, 2020

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery Meta-analysis725.jpg

News Daily News

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery: Meta-analysis

Michael O'Riordan

October 23, 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

October 21, 2020

Under ISCHEMIA’s Long Shadow, Cardiologists Ponder Shifting Guidelines, Care

News Conference News TCT 2020

Under ISCHEMIA’s Long Shadow, Cardiologists Ponder Shifting Guidelines, Care

Michael O'Riordan

October 19, 2020

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

News Conference News TCT 2020

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

October 15, 2020

Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease: The Disrupt CAD III Study

Presentation TCT 2020

Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease: The Disrupt CAD III Study

Presenter: Dean J. Kereiakes

October 15, 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

News Conference News TCT 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

October 14, 2020

TICO-STEMI: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor With Aspirin in STEMI

Presentation TCT 2020

TICO-STEMI: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor With Aspirin in STEMI

Presenter: Byeong-Keuk Kim

October 14, 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

News Conference News TCT 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

October 14, 2020

Effect of pre-hospital crushed prasugrel tablets in patients with STEMI planned for primary percutaneous coronary intervention: The COMPARE CRUSH Trial

Presentation TCT 2020

Effect of pre-hospital crushed prasugrel tablets in patients with STEMI planned for primary percutaneous coronary intervention: The COMPARE CRUSH Trial

Presenter: George Vlachojannis

October 14, 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

October 14, 2020

Study Affirms Thrombotic Risk in COVID-19

News Daily News

Study Affirms Thrombotic Risk in COVID-19

October 01, 2020

TCTMD’s Top 10 Most Popular Stories for September 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2020

October 01, 2020

October 2020 News Roundup

News Opinion CV Team Dispatch

October 2020 News Roundup

October 01, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.